TCM
PHAS

Towercrest Capital Management’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Towercrest Capital Management’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,051,940
Closed -$1.39M – 94
2022
Q1 		$1.39M Buy
+1,051,940
New +$1.71M 0.27% 45

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Towercrest Capital Management's PHAS Position: Q2 2022 in Review

Towercrest Capital Management sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q2 2022, closing a stake of 1,051,940 shares — an estimated $1.39M sold.

Towercrest Capital Management first reported a position in PHAS in Q1 2022 and held it in 1 quarter. The position peaked at $1.39M in Q1 2022. 49 funds tracked by Wall St. Rank hold PHAS as of Q2 2022.

  • Towercrest Capital Management reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Towercrest Capital Management sold 1,051,940 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $1.39M.
  • Towercrest Capital Management first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Towercrest Capital Management's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $1.39M in Q1 2022.
  • 49 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Towercrest Capital Management's 13F filing for Q2 2022, filed 11 Aug 2022.